Cargando…

BETting on combination to overcome PARPi resistance

Detalles Bibliográficos
Autores principales:	Zhang, Youyou, Dang, Chi V., Zhang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689556/ https://www.ncbi.nlm.nih.gov/pubmed/29156666 http://dx.doi.org/10.18632/oncotarget.21446

Ejemplares similares

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018)

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
por: Wyce, Anastasia, et al.
Publicado: (2018)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
por: Kumari, Anju, et al.
Publicado: (2023)

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
por: Zhang, Zengfu, et al.
Publicado: (2023)

The Importance of Overcoming Resistance
por: Paradis, Norman A.
Publicado: (2020)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Overcoming treatment resistance in acute promyelocytic leukemia and beyond
por: Fung, Tsz Kan, et al.
Publicado: (2013)

Elongation vs stalling: place your BET
por: Donato, Elisa, et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Early intervention in mental health: The best bet
por: The Lancet Regional Health – Southeast Asia
Publicado: (2022)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer
por: Wang, Xu, et al.
Publicado: (2022)

Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
por: Wu, Yutuan, et al.
Publicado: (2022)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Happy 25th birthday, Bet v 1!
por: Jensen-Jarolim, Erika
Publicado: (2014)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

We shall overcome (drug resistance) some day
por: Sharma, Geeta G., et al.
Publicado: (2019)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Overcoming drug resistance in glioblastoma: new options in sight?
por: Kopecka, Joanna, et al.
Publicado: (2021)

Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization
por: Zhang, Pingzhao, et al.
Publicado: (2017)

MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment
por: Mori, Federica, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3dbnnf6o8dj0gfau9hch0qivtg